Inhibrx Biosciences (INBX) Competitors $33.61 +0.11 (+0.33%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$33.64 +0.03 (+0.09%) As of 10/8/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCRShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Dyne Therapeutics Apogee Therapeutics Cogent Biosciences Tilray Brands AbCellera Biologics Immunocore Ocular Therapeutix (NASDAQ:OCUL) and Inhibrx Biosciences (NASDAQ:INBX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Which has higher valuation and earnings, OCUL or INBX? Inhibrx Biosciences has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M32.52-$193.51M-$1.28-9.30Inhibrx Biosciences$200K2,433.36$1.69B-$10.58-3.18 Is OCUL or INBX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Ocular Therapeutix's return on equity of -71.92% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Inhibrx Biosciences N/A -137.83%-76.31% Do institutionals and insiders have more ownership in OCUL or INBX? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer OCUL or INBX? In the previous week, Ocular Therapeutix had 26 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 28 mentions for Ocular Therapeutix and 2 mentions for Inhibrx Biosciences. Ocular Therapeutix's average media sentiment score of 0.37 beat Inhibrx Biosciences' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 6 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, OCUL or INBX? Ocular Therapeutix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Do analysts prefer OCUL or INBX? Ocular Therapeutix presently has a consensus target price of $22.63, suggesting a potential upside of 89.97%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SummaryOcular Therapeutix beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$485.26M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-3.1821.5785.5627.61Price / Sales2,433.36271.42535.65201.06Price / Cash0.2947.1237.9261.55Price / Book3.6410.1413.036.76Net Income$1.69B-$52.31M$3.30B$275.88M7 Day Performance-4.14%5.14%4.35%2.81%1 Month Performance13.62%14.68%9.50%9.24%1 Year Performance114.49%30.98%85.16%35.42% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences1.0171 of 5 stars$33.61+0.3%N/A+110.2%$485.26M$200K-3.18166News CoveragePositive NewsAnalyst ForecastOCULOcular Therapeutix3.9704 of 5 stars$10.97-3.9%$22.13+101.7%+27.8%$1.99B$56.66M-8.57230Analyst ForecastInsider TradeANIPANI Pharmaceuticals3.626 of 5 stars$92.06+2.7%$97.29+5.7%+61.4%$1.95B$614.38M-119.56600Analyst DowngradeVERAVera Therapeutics2.7341 of 5 stars$30.94+2.7%$63.00+103.6%-21.1%$1.92BN/A-8.6440News CoveragePositive NewsAnalyst ForecastTWSTTwist Bioscience3.7473 of 5 stars$31.85+2.5%$48.90+53.5%-22.9%$1.88B$362.27M-21.97990Trending NewsAnalyst ForecastInsider TradeDYNDyne Therapeutics3.5261 of 5 stars$12.65-3.1%$34.07+169.3%-56.1%$1.86BN/A-3.28100Analyst ForecastAPGEApogee Therapeutics3.2182 of 5 stars$39.82-0.2%$92.63+132.6%-15.8%$1.84BN/A-9.6491News CoverageAnalyst ForecastCOGTCogent Biosciences2.8164 of 5 stars$15.90+0.9%$20.00+25.8%+43.6%$1.79BN/A-8.9380Analyst ForecastHigh Trading VolumeTLRYTilray Brands2.0573 of 5 stars$1.58-2.5%$1.94+22.6%+4.2%$1.78B$210.48M-0.682,842Analyst ForecastABCLAbCellera Biologics2.6493 of 5 stars$5.87-0.5%$8.00+36.3%+140.1%$1.75B$32.88M-10.67500Analyst ForecastIMCRImmunocore2.6213 of 5 stars$34.01-0.6%$56.89+67.3%+11.2%$1.72B$310.20M-85.03320Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Ocular Therapeutix Alternatives ANI Pharmaceuticals Alternatives Vera Therapeutics Alternatives Twist Bioscience Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Cogent Biosciences Alternatives Tilray Brands Alternatives AbCellera Biologics Alternatives Immunocore Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
